Publications by authors named "Oriol Cardus"
Chimeric antigen receptor-T (CAR-T) cells directed against B-cell maturation antigen (BCMA) are an effective treatment for multiple myeloma (MM), but short persistence and frequent relapses are challenges for this immunotherapy. This lack of durability has been attributed to the premature terminal differentiation of CAR-T cells which prevents the formation of long-lived memory cells that maintain anti-tumour responses. To improve long-term efficacy, we used CRISPR/Cas9-mediated gene editing to ablate the expression of the transcription factor Blimp-1.
View Article and Find Full Text PDFArticle Synopsis
- TIGIT blockade in an ex vivo model reduced malignant plasma cells in multiple myeloma patients, but only half responded, leading to an investigation of whether increased TIGIT ligand expression inhibits T-cell immune responses.
- Researchers characterized bone marrow macrophages through flow cytometry and studied the impact of TIGIT ligands on plasma cell survival and gene expression using advanced technologies.
- Findings revealed decreased macrophage frequency in multiple myeloma, with increased malignant plasma cells surviving due to the presence of PVR ligand, which also inhibited T-cell effectiveness and increased TIGIT expression, contributing to resistance against TIGIT blockade.
Waldenström macroglobulinaemia (WM) is characterized by recurrent somatic mutations in MYD88 and CXCR4 genes. However, limitations arise when analysing these mutations in IgM monoclonal gammopathy of undetermined significance (MGUS) or smouldering WM (SWM) given the lower tumour load. Here, we used droplet digital polymerase chain reaction (ddPCR) to analyse MYD88 L265P and CXCR4 S338* mutations (C1013G and C1013A) in unsorted bone marrow (BM) or cell-free DNA (cfDNA) samples from 101 IgM MGUS and 69 SWM patients.
View Article and Find Full Text PDF